Skip to content

Clozapine for the Treatment-Resistant Schizophrenic

John Michael Kane

Archives of General Psychiatry · 1988 · 4,185 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Kane, J. M. (1988). Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45(9), 789. https://doi.org/10.1001/archpsyc.1988.01800330013001

In text: (Kane, 1988)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis. This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks. Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks. Two hundred sixty-eight patients were entered in the double-blind comparison. When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients. Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas. Although no cases of agranulocytosis occurred during this relatively brief study, in our view, the apparently increased comparative risk requires that the use of clozapine be limited to selected treatment-resistant patients.

  1. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia1987
  2. A Rating Scale for Mania: Reliability, Validity and Sensitivity1978
  3. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia2005
  4. Screening for Serious Mental Illness in the General Population2003
  5. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies2021

Metadata from OpenAlex (CC0). Citations are generated from the published record.